LEO Pharma Acquires Replay for $50 Million to Advance HSV Gene Therapy Platform for Rare Skin Diseases
Key Insights
LEO Pharma has entered into a definitive agreement to acquire Replay (search) for $50 million upfront, adding a next-generation herpes simplex virus (search) (HSV) gene therapy platform to its dermatology pipeline.
The acquisition targets rare genetic skin diseases, with Replay (search)'s lead program focusing on dystrophic epidermolysis bullosa (search) (DEB), a devastating condition that causes fragile, easily blistered skin.
Replay (search)'s HSV gene therapy (search) platform leverages the virus's natural tropism for skin cells and ability to deliver large genes through a topical gel formulation applied directly to the skin.
LEO Pharma, a global leader in medical dermatology, has announced a definitive agreement to acquire Replay (search), a gene therapy company focused on developing transformative treatments for rare genetic dermatological conditions. The acquisition, valued at $50 million upfront plus milestone payments and tiered single-digit royalties, adds a next-generation herpes simplex virus (search) (HSV) gene therapy platform to LEO Pharma's pipeline.
HSV Gene Therapy Platform for Genetic Skin Diseases
Replay (search)'s proprietary platform leverages engineered herpes simplex virus (search) vectors that offer natural tropism for skin cells and the ability to redose patients over time. The genetically modified HSV therapy is formulated as a topical gel that targets deficient genes when applied directly to the skin, making it particularly well-suited for addressing rare, genetically driven dermatological conditions.
"Replay (search)'s HSV gene therapy (search) platform holds significant promise for patients with rare genetic skin diseases, and realizing its full potential requires focused expertise in medical dermatology - an area where LEO Pharma brings decades of leadership, scale and proven execution," said Christophe Bourdon, CEO of LEO Pharma.
The viral gene therapy approach uses engineered viruses to deliver therapeutic genetic material into cells to treat disease at its source. Replay (search)'s HSV platform is uniquely capable of delivering large genes, addressing a key limitation in gene therapy applications for complex genetic conditions.
Lead Program Targets Dystrophic Epidermolysis Bullosa
Replay (search)'s lead drug candidate is currently in preclinical studies for the treatment of dystrophic epidermolysis bullosa (search) (DEB), a rare genetic condition that causes the skin to be fragile and blister easily. The disease leads to painful chronic wounds that heal slowly and poorly, often resulting in scar tissue and skin cancer (search).
"Dystrophic epidermolysis bullosa (search) remains one of the most devastating genetic skin diseases with significant unmet need. Pairing Replay (search)'s HSV gene therapy (search) platform with LEO Pharma's dermatology expertise and global infrastructure is exactly the kind of combination the DEB community needs," said Martin Steiner, Managing Director at DEBRA Research (search), a non-profit organization dedicated to advancing effective treatments and cures for DEB.
Strategic Expansion in Rare Dermatology
The acquisition aligns with LEO Pharma's strategy of investing in high-impact opportunities in dermatology and positions the company at the forefront of next-generation gene therapy. LEO Pharma identified Replay (search) using its AI-powered scouting platform, Innoviewer™, as a high-potential opportunity.
"On top of all the pipelines that we have now, we're entering the promise of gene therapy," CEO Christophe Bourdon told Reuters. The deal builds on LEO Pharma's existing rare skin disease portfolio, including its Boehringer Ingelheim partnership for Spevigo and a DEBRA research (search) tie-up targeting epidermolysis bullosa (search).
Chief Scientific Officer Jacob Pontoppidan Thyssen noted the platform's broader potential: "There is a preclinical proof of concept that makes us believe that we can really unfold it into several diseases."
Integration and Future Development
LEO Pharma will leverage Replay (search)'s world-class HSV design and manufacturing specialist team to drive continued innovation and program advancement as it joins the company's dermatology portfolio. The acquisition brings together LEO Pharma's six decades of dermatology expertise with Replay's specialized gene therapy platform.
"Natural tropism for skin cells and the ability to redose patients make HSV uniquely suited to treating rare genetic dermatological conditions. Together with LEO Pharma's decades of dermatology leadership and global infrastructure, purpose-built for skin diseases, we can bring therapies to the patients who need them most," said Lachlan MacKinnon, CEO of Replay (search).
The purchase comes as LEO Pharma prepares for a possible stock-market listing, making growth deals increasingly important as the company seeks to demonstrate future revenue potential to investors. After a leadership and organizational reshuffle four years ago, LEO Pharma has been sharpening its focus on dermatology, with stronger results providing more room for strategic acquisitions.